Portugal
Anticancer biotechnology created by Portuguese scientist fits 5.9 million to test on humans
Publication: ECO
Author: Mariana Bandeira
Source published: 10/11/2026, 09:30:42 UTC
Briefing created: 22/11/2026, 20:31:17 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 09:41:24 UTC.
Briefings
Portuguese biotech Neobe Therapeutics secured 5.9 million euros from ARC Ventures to advance its NEO22 therapy for solid tumors. The company uses genetically modified bacteria to degrade tumor barriers, aiming to deliver treatments to cancer sites. CEO Pedro Correa de Sampaio led the funding round, which also attracted investors from Faber and Macmillan Ventures, raising total capital to over 9.5 million euros. The company plans to proceed with pre-clinical studies before human trials, with an IND approval target for 2028.
Key points
- Neobe Therapeutics, led by Portuguese CEO Pedro Correa de Sampaio, raised 5.9 million euros from ARC Ventures to fund the development of its NEO22 therapy for solid tumors.
- The company's technology uses genetically modified bacteria to degrade tumor barriers, enabling treatments to reach cancer sites that current therapies cannot access.
Context
Neobe Therapeutics is a UK-based biotech firm founded in 2021 by Portuguese scientist Pedro Correa de Sampaio, aiming to solve the delivery barrier of solid tumor treatments. The company is expanding its presence in Lisbon and partnering with Portuguese venture capital firms to support its pre-clinical research and IND approval process.
Limitations
The evidence covers only the 5.9 million euro funding round and the company's strategic goals. It does not provide data on clinical trial outcomes, patient enrollment numbers, or specific efficacy metrics for the NEO22 therapy.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/11/2026, 20:31:17 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
IPFS archive pending.